Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Directorate Change

29 Nov 2023 07:01

RNS Number : 9803U
Benchmark Holdings PLC
29 November 2023
 

29 November 2023

 

Benchmark Holdings plc

("Benchmark" or the "Company")

Directorate Change

The Company is pleased to announce the appointment of Jonathan Esfandi as Non-Executive Director. Mr Esfandi is the founder and managing partner at JNE Partners LLP. 

Mr. Esfandi will act as shareholder representative of JNE Partners LLP, a significant shareholder of the Company, and therefore the Board has concluded that he is not an independent director. 

Laura Lavers, who joined the Board in November 2022, will retire from the Board as a Non-Executive Director with effect from today.

 

Peter George, Chairman, commented:

"We welcome Jonathan to the Board and look forward to working together. On behalf of the Board, I wish to thank Laura Lavers for her contribution over the past year."

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in connection with the appointment of Jonathan to the Board of the Company:

Full Name: Jonathan Esfandi

Age: 49

Current Directorships: 

JNE PARTNERS LLP

JNE PARTNERS (UK) SERVICES LTD

Former Directorships (previous five years): None within the past five years

Beneficial interest in the equity securities of Benchmark Holdings plc: No direct beneficial interest. Funds managed by JNE Partners LLP have a holding of 169,263,811 shares in Benchmark

There is no further information required to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

Enquiries

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Deutsche Numis (Nominated Adviser and Broker)

Tel: 020 7260 1000

Freddie Barnfield, Duncan Monteith, Sher Shah

MHP

Tel: 020 3128 8004

Katie Hunt, Reg Hoare

benchmark@mhpgroup.com

 

Equity Development

Hannah Crowe

 

Tel: 020 7065 2692

 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADXBDBXGDDGXI
Date   Source Headline
31st Mar 20227:00 amRNSTotal Voting Rights
21st Mar 20227:00 amRNSBlock Listing Six Monthly Return
28th Feb 20229:15 amRNSTotal Voting Rights
22nd Feb 20227:00 amRNSQ1 Results
10th Feb 20225:37 pmRNSResult of AGM
7th Feb 20227:00 amRNSNotice of Q1 Results
4th Feb 20224:41 pmRNSSecond Price Monitoring Extn
4th Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTotal Voting Rights
20th Jan 20227:00 amRNSHolding(s) in Company
31st Dec 20217:00 amRNSTotal Voting Rights
24th Dec 20217:00 amRNSHolding(s) in Company
13th Dec 20213:46 pmRNSHolding(s) in Company
10th Dec 20214:17 pmRNSPosting of Annual Report and Notice of AGM
8th Dec 202112:02 pmRNSDIRECTOR SHARE OPTIONS
2nd Dec 20215:58 pmRNSAnnual Report available on website
1st Dec 202110:12 amRNSHolding(s) in Company
1st Dec 202110:02 amRNSTotal Voting Rights
29th Nov 20212:38 pmRNSPCA Dealing
29th Nov 202110:50 amRNSANNOUNCEMENT REGARDING DIRECTOR SUBSCRIPTIONS
29th Nov 20217:01 amRNSPlacing and Appointment of non-Executive Director
29th Nov 20217:00 amRNSQ4 Results
29th Nov 20217:00 amRNSFull Year Results
12th Nov 20217:00 amRNSInvestor Presentation covering Full Year Results
29th Oct 20217:00 amRNSTotal Voting Rights
18th Oct 20217:00 amRNSTrading Statement
30th Sep 20217:00 amRNSTotal Voting Rights
23rd Sep 20217:00 amRNSEnvironmental recognition for CleanTreat®
21st Sep 20217:00 amRNSBlock Listing Six Monthly Return
31st Aug 20217:00 amRNSTotal Voting Rights
25th Aug 20217:00 amRNSEquity Development Investor Webinar
24th Aug 20217:00 amRNSQ3 Results
30th Jul 20217:00 amRNSTotal Voting Rights
15th Jul 20213:00 pmRNSAdoption of MRL for Ectosan Vet in Norway
2nd Jul 20213:20 pmRNSBMK08+CleanTreat and Trading Update
30th Jun 20217:00 amRNSTotal Voting Rights
21st Jun 20214:41 pmRNSSecond Price Monitoring Extn
21st Jun 20214:36 pmRNSPrice Monitoring Extension
2nd Jun 20214:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20214:35 pmRNSPrice Monitoring Extension
28th May 20217:00 amRNSTotal Voting Rights
25th May 20217:00 amRNSDirector Dealings
18th May 20217:00 amRNSSecond Quarter and Interim results
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSNotice of Q2 and Interim Results
16th Apr 202111:00 amRNSBMK08+CleanTreat Update
31st Mar 20213:41 pmRNSDirector Dealings
31st Mar 20217:00 amRNSTotal Voting Rights
30th Mar 20217:00 amRNSListing of existing senior secured NOK bond
26th Mar 20218:24 amRNSBMK08+CleanTreat Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.